Insight on USFDA approval of Allergan’s Ubrelvy
Allergan plc announced that the US Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Ubrelvy (ubrogepant) for... Read More
Case Analysis: Insight on AbbVie’s acquisition of Allergan
On June 25, 2019, AbbVie Inc. and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie... Read More
Case Study: Allergan’s $2.48 billion acquisition Zeltiq Aesthetics
Posted on13 Feb 2017
Comments0
Botox maker Allergan Plc agrees to acquire body-contouring product maker Zeltiq Aesthetics Inc for about $2.48 billion, adding muscle to its line-up... Read More
Allergan’s Rhofade cream got USFDA approval for treating persistent facial erythema associated with rosacea
Posted on23 Jan 2017
Comments0
Allergan plc, a leading global pharmaceutical company, has announced the approval of Rhofade cream by the US Food and Drug Administration (FDA)... Read More
Allergan’s acquisition of Chase Pharmaceuticals – Cipla divests its 16.7% stake in Chase Pharmaceuticals Corp
Allergan plc announced acquisition of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders... Read More
MedImmune’s out-licensing deal with Allergan for MEDI2070
AstraZeneca announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the... Read More
Allergan receives US FDA approval for Restasis Multidose for chronic dry eye
Allergan Introduces RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%, a New Delivery System for the One and Only FDA Approved Treatment to Help... Read More
Allergan to acquire California-based clinical-stage biopharma company, Tobira Therapeutics for $1.7 billion
Allergan plc, a leading global pharmaceutical company, and Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for... Read More
Allergan acquires biopharma company, Akarna Therapeutics
Allergan plc, a leading global pharmaceutical company, has acquired Akarna Therapeutics Ltd., a privately held biopharmaceutical company focused on developing novel small... Read More
Allergan to acquire Vitae Pharma
Allergan, the maker of Botox, will Vitae Pharmaceuticals, a drugmaker focused on dermatology segment at $639 million (€567 million). Vitae is developing... Read More